Jean S Reinhold, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 36901 American Way, Avon, OH 44011 Phone: 440-930-6200 Fax: 440-930-6201 |
Rebecca N Starck, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 36901 American Way, Avon, OH 44011 Phone: 440-930-6200 Fax: 440-930-6201 |
Alison D Lemberg, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 36901 American Way, Avon, OH 44011 Phone: 440-333-5460 Fax: 440-356-2398 |
Salena D Zanotti, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 36901 American Way, Avon, OH 44011 Phone: 440-930-6200 Fax: 440-930-6201 |
Anthony E Bacevice Jr., MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1997 Healthway Dr, Suite 203, Avon, OH 44011 Phone: 440-988-6884 Fax: 440-988-6896 |
Dr. Kathryn Rae Goebel, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 36901 American Way, Suite A, Avon, OH 44011 Phone: 440-930-6200 |
News Archive
New research from the Hebrew University of Jerusalem shows that a carefully scheduled high-fat diet can lead to a reduction in body weight and a unique metabolism in which ingested fats are not stored, but rather used for energy at times when no food is available.
As the population of older adults in the United States continues to grow and becomes more diverse, health concerns increase in parallel.
The time may be fast approaching for researchers to take better advantage of the vast amount of valuable patient information available from U.S. electronic health records. Lian Duan, an NJIT computer scientist with an expertise in data mining, has done just that with the recent publication of "Adverse Drug Effect Detection," IEEE Journal of Biomedical and Health Informatics (March, 2013).
SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).
› Verified 7 days ago